secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001193125-23-077876
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd FY2022 net loss $241.3M; advancing VYD222 mAb into clinic
-----------------------------------------------------------------

- Cash, cash equivalents and marketable securities $372M as of Dec 31, 2022, expected to fund operations into H2 2024.
- Net loss $241.3M ($2.23 per share) for FY2022 vs $226.8M ($5.32 per share) in FY2021.
- R&D expenses $183.6M, down slightly from $190.4M in FY2021.
- Advancing VYD222 into Phase 1 clinical trial in Q1 2023; in vitro data shows neutralizing activity against XBB.1.5.
- Appointed Jeremy Gowler as COO and promoted Pete Schmidt to CMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/0001193125-23-077876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312523077876/d450944d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-077876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer